AU2021370788A1 - Homodimeric and heterodimeric proteins comprising butyrophilin - Google Patents

Homodimeric and heterodimeric proteins comprising butyrophilin Download PDF

Info

Publication number
AU2021370788A1
AU2021370788A1 AU2021370788A AU2021370788A AU2021370788A1 AU 2021370788 A1 AU2021370788 A1 AU 2021370788A1 AU 2021370788 A AU2021370788 A AU 2021370788A AU 2021370788 A AU2021370788 A AU 2021370788A AU 2021370788 A1 AU2021370788 A1 AU 2021370788A1
Authority
AU
Australia
Prior art keywords
cancer
domain
amino acid
protein
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021370788A
Other languages
English (en)
Other versions
AU2021370788A9 (en
Inventor
Suresh DE SILVA
George FROMM
Taylor Schreiber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shattuck Labs Inc
Original Assignee
Shattuck Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shattuck Labs Inc filed Critical Shattuck Labs Inc
Publication of AU2021370788A1 publication Critical patent/AU2021370788A1/en
Publication of AU2021370788A9 publication Critical patent/AU2021370788A9/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021370788A 2020-10-26 2021-04-14 Homodimeric and heterodimeric proteins comprising butyrophilin Abandoned AU2021370788A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063105744P 2020-10-26 2020-10-26
US63/105,744 2020-10-26
PCT/US2021/027294 WO2022093310A1 (en) 2020-10-26 2021-04-14 Homodimeric and heterodimeric proteins comprising butyrophilin

Publications (2)

Publication Number Publication Date
AU2021370788A1 true AU2021370788A1 (en) 2023-06-22
AU2021370788A9 AU2021370788A9 (en) 2024-10-24

Family

ID=81384237

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021370788A Abandoned AU2021370788A1 (en) 2020-10-26 2021-04-14 Homodimeric and heterodimeric proteins comprising butyrophilin

Country Status (7)

Country Link
US (1) US20230416333A1 (https=)
EP (1) EP4232065A4 (https=)
JP (1) JP2023546725A (https=)
CN (1) CN116801897A (https=)
AU (1) AU2021370788A1 (https=)
CA (1) CA3196533A1 (https=)
WO (1) WO2022093310A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024511992A (ja) * 2021-03-16 2024-03-18 シャタック ラボ，インコーポレイテッド ガンマデルタｔ細胞刺激
US20250179144A1 (en) * 2021-12-09 2025-06-05 The University Of Melbourne Modified Butyrophilin and Butyrophilin Complexes
WO2024006907A2 (en) * 2022-06-29 2024-01-04 Shattuck Labs, Inc. B7h3-targeted gamma delta t cell modulation
WO2024006889A2 (en) * 2022-06-29 2024-01-04 Shattuck Labs, Inc. Cd20-targeted gamma delta t cell modulation
CN118388647A (zh) * 2022-06-30 2024-07-26 深圳市乐土生物医药有限公司 一种分离的Claudin18.2抗体及其应用
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
CN121752279A (zh) * 2023-06-30 2026-03-27 科瑞特医药公司 工程化嵌合融合蛋白组合物及其使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2766200C1 (ru) * 2015-10-01 2022-02-09 Хит Байолоджикс, Инк. Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков
WO2020047329A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Chimeric proteins comprising extracellular domains and uses thereof
US11098093B2 (en) * 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells
WO2020146393A1 (en) * 2019-01-07 2020-07-16 Shattuck Labs. Inc. Heterodimeric proteins for modulating gamma delta t cells

Also Published As

Publication number Publication date
EP4232065A4 (en) 2024-10-16
JP2023546725A (ja) 2023-11-07
CA3196533A1 (en) 2022-05-05
AU2021370788A9 (en) 2024-10-24
EP4232065A1 (en) 2023-08-30
CN116801897A (zh) 2023-09-22
WO2022093310A1 (en) 2022-05-05
US20230416333A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
JP7620045B2 (ja) Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
US10988517B2 (en) Heterodimeric proteins for modulating gamma delta T cells
US11643447B2 (en) Heterodimeric proteins for modulating gamma delta T cells
US20230416333A1 (en) Homodimeric and heterodimeric proteins comprising butyrophilin
EP3356393A1 (en) Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
RU2775490C2 (ru) Химерные белки на основе tigit и light

Legal Events

Date Code Title Description
SREP Specification republished
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period